ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.

Share on Pinterest Getty Images/Dragoljub Bankovic The FreeStyle Libre is a continuous glucose monitoring (CGM) system that doesn’t require a blood sample from a finger stick. It’s ...

Abbott’s FreeStyle Libre continuous glucose monitoring technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes, according ...

Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to a ...

(RTTNews) - Abbott Laboratories (ABT) Thursday announced positive data from REFLECT studies of its FreeStyle Libre continuous glucose monitoring (CGM) technology. The REFLECT studies, funded by ...

Abbott's REFLECT studies indicate that FreeStyle Libre use is linked to a decrease in hospitalisation risk for heart ...

Abbott Park, Illinois Saturday, May 17, 2025, 12:00 Hrs [IST] ...

Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to ...

They let you keep track of your blood sugar levels in a less invasive way. One type of CGM is Abbott’s Freestyle Libre. Medicare took some time to accept these devices. However, for the last few ...

Abbott's steady cash flow, premium margins, and expanding diabetes and medtech franchises make it a long-term winner. See why ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...